Oncimmune Holdings PLC GRANT OF OPTIONS (1020D)
April 24 2017 - 3:18AM
UK Regulatory
TIDMONC
RNS Number : 1020D
Oncimmune Holdings PLC
24 April 2017
24 April 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
GRANT OF OPTIONS
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, announces that on 21 April 2017,
options over 23,872 ordinary shares of 1 pence each in the capital
of the Company ("Ordinary Shares") were awarded to certain US staff
under the Oncimmune Holdings Plc Incentive Stock Option Plan (as
amended from the Oncimmune Limited Incentive Stock Option Plan that
became effective 27 July 2009). The options are subject to the
rules of the Incentive Stock Option Plan and vest in five equal
annual parts, the first fifth vesting on 20 April 2018 and each
year thereafter for a further four years, subject to continued
employment. The options are exercisable at 131 pence, being the
mid-market closing price of the Ordinary Shares on 20 April
2017.
The Company also announces that on 21 April 2017, options over
30,534 ordinary shares of 1 pence each in the capital of the
Company ("Ordinary Shares") were awarded to a member of UK staff
under the Oncimmune Holdings Plc 2016 Unapproved & EMI Share
Option Plan. The options are subject to the rules of the Oncimmune
Holdings Plc 2016 Unapproved & EMI Share Option Plan and vest
in five equal annual parts, the first fifth vesting on 8 January
2018 and each year thereafter for a further four years, subject to
continued employment. The options are exercisable at 131 pence,
being the mid-market closing price of the Ordinary Shares on 20
April 2017.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey
Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGIGDSUBDBGRS
(END) Dow Jones Newswires
April 24, 2017 04:18 ET (08:18 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024
